drugset / Trial / NCT05953038

LSD Occupancy of the Serotonin 2A Receptor in the Human Brain

NCT05953038

Phase 0 Active not recruiting 40 enrolled Rigshospitalet, Denmark
NaSingle-groupOpen-labelBasic science

Summary

The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using \[11C\]CIMBI-36 positron emission tomography.

Timeline

Start
2023-11-08
Primary completion
2027-12
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lysergic Acid Diethylamide Other / unclassified 25 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 50 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 75 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 100 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 125 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 150 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 175 ug Oral
Subject Lysergic Acid Diethylamide Other / unclassified 200 ug Oral

Indications

No indication recorded.